

Neuropsychiatric symptoms in Alzheimer's disease: Past and future

Alzheimer's and Dementia

9, 602-608

DOI: 10.1016/j.jalz.2012.12.001

Citation Report

#	ARTICLE	IF	CITATIONS
1	Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 321.	2.0	61
2	Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 759-773.	2.6	46
3	The Independent Contributions of Cognitive Impairment and Neuropsychiatric Symptoms to Everyday Function in Older Adults. <i>Clinical Neuropsychologist</i> , 2014, 28, 215-236.	2.3	58
4	Role of citalopram in the treatment of agitation in Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2014, 4, 345-349.	2.2	13
5	Antiepileptic Drugs for the Treatment of Agitation and Aggression in Dementia: Do They Have a Place in Therapy?. <i>Drugs</i> , 2014, 74, 1747-1755.	10.9	49
6	Behavioral and Psychological Symptoms in Alzheimer's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	75
7	Effect of Citalopram on Agitation in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 682.	7.4	447
8	Management of Behavioral and Psychological Symptoms of Dementia. <i>Current Geriatrics Reports</i> , 2014, 3, 259-272.	1.1	7
9	Can antidepressant medication relieve agitation in Alzheimer's disease?. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 969-971.	2.8	6
10	Psychosis in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2014, 75, 542-552.	1.3	153
11	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2691-2700.	3.1	70
12	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 819-833.	2.6	53
13	A practical algorithm for managing Alzheimer's disease: what, when, and why?. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 307-323.	3.7	68
14	Cognitive phenotype of psychotic symptoms in Alzheimer's disease: evidence for impaired visuoperceptual function in the misidentification subtype. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1147-1155.	2.7	15
15	A Review of Pharmacological Treatments for Depression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 15-34.	2.6	7
16	Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease. <i>Harvard Review of Psychiatry</i> , 2015, 23, 377-393.	2.1	33
17	Alternative pharmacological treatment options for agitation in Alzheimer's disease. <i>Geriatric Care</i> , 2015, 1, .	0.2	1
18	Role of Hybrid Brain Imaging in Neuropsychiatric Disorders. <i>Diagnostics</i> , 2015, 5, 577-614.	2.6	11

#	ARTICLE	IF	CITATIONS
19	Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 67.	3.4	21
20	Regional Coherence Changes in Alzheimer's Disease Patients with Depressive Symptoms: A Resting-State Functional MRI Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 603-611.	2.6	16
21	Aberrant Functional Connectivity Architecture in Alzheimer's Disease and Mild Cognitive Impairment: A Whole-Brain, Data-Driven Analysis. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	30
22	Validity and Reliability of the European Portuguese Version of Neuropsychiatric Inventory in an Institutionalized Sample. <i>Journal of Clinical Medicine Research</i> , 2015, 7, 21-28.	1.2	15
23	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. <i>International Psychogeriatrics</i> , 2015, 27, 7-17.	1.0	244
24	Comorbidities in Neurology: Is adenosine the common link?. <i>Neuropharmacology</i> , 2015, 97, 18-34.	4.1	80
25	Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset. <i>Alzheimer's and Dementia</i> , 2015, 11, 1349-1357.	0.8	93
26	Beyond Memory: A Focus on the Other Neuropsychiatric Symptoms of Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 115-118.	1.2	17
27	Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 12.	6.2	96
28	Assessment and management of behavioral and psychological symptoms of dementia. <i>BMJ</i> , The, 2015, 350, h369-h369.	6.0	801
29	Modifiable Predictors of Dementia in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. <i>American Journal of Psychiatry</i> , 2015, 172, 323-334.	7.2	382
30	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 7.	6.2	47
31	Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care. <i>Neurodegenerative Disease Management</i> , 2015, 5, 77-83.	2.2	18
32	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2015, 27, 181-197.	1.0	29
33	Advancements in the treatment of agitation in Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1649-1656.	1.8	28
34	Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits?. <i>Molecular Aspects of Medicine</i> , 2015, 43-44, 25-37.	6.4	223
35	Neuropsychiatric symptoms, ϵ -APOE ϵ 4, and the risk of incident dementia. <i>Neurology</i> , 2015, 84, 935-943.	1.1	101
36	Association between pain, neuropsychiatric symptoms, and physical function in dementia: a systematic review and meta-analysis. <i>BMC Geriatrics</i> , 2015, 15, 49.	2.7	61

#	ARTICLE	IF	CITATIONS
37	Managing anxiety associated with neurodegenerative disorders. F1000prime Reports, 2015, 7, 05.	5.9	7
38	Neuropsychiatric Symptoms in Dementia: A Cause or Consequence?. American Journal of Psychiatry, 2015, 172, 410-411.	7.2	5
39	Depression associated with dementia. Zeitschrift Fur Gerontologie Und Geriatrie, 2015, 48, 305-311.	1.8	54
40	Posterior Cortical Atrophy. Psychiatric Clinics of North America, 2015, 38, 211-220.	1.3	27
41	Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2581-2588.	1.8	43
42	Direct medical costs and source of cost differences across the spectrum of cognitive decline: A population-based study. Alzheimer's and Dementia, 2015, 11, 917-932.	0.8	70
43	Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neuroscience and Biobehavioral Reviews, 2015, 49, 157-170.	6.1	31
44	Psychotic disorders in women in later life. , 0, , 320-336.		0
45	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	1.4	50
46	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2016, 53, 1609-1616.	2.6	35
47	Neural Correlates for Apathy: Frontal-Prefrontal and Parietal Cortical- Subcortical Circuits. Frontiers in Aging Neuroscience, 2016, 8, 289.	3.4	75
48	Behavioural Phenotyping of APPswe/PS1 ^{E9} Mice: Age-Related Changes and Effect of Long-Term Paroxetine Treatment. PLoS ONE, 2016, 11, e0165144.	2.5	34
50	A Bayesian model of psychosis symptom trajectory in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2016, 31, 204-210.	2.7	15
51	and Citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. British Journal of Clinical Pharmacology, 2016, 82, 784-792.	2.4	54
52	Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach. Journal of Alzheimer's Disease, 2016, 51, 427-437.	2.6	26
53	Apathy and Attentional Biases in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 837-846.	2.6	19
54	Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Archives of Gerontology and Geriatrics, 2016, 65, 231-238.	3.0	38
55	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. American Journal of Psychiatry, 2016, 173, 473-480.	7.2	63

#	ARTICLE	IF	CITATIONS
56	Managing Neuropsychiatric Symptoms of Neurodegenerative Diseases. , 2016, , 233-253.		0
57	An Education Intervention to Enhance Staff Self-Efficacy to Provide Dementia Care in an Acute Care Hospital in Canada. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 664-677.	1.9	33
58	Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases. Drug Development Research, 2016, 77, 458-468.	2.9	7
59	Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study. Journal of Alzheimer's Disease, 2016, 50, 839-845.	2.6	19
60	Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. Molecular Neurodegeneration, 2016, 11, 16.	10.8	96
61	Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers' well-being: ALSOVA 3-year follow-up. International Journal of Geriatric Psychiatry, 2016, 31, 273-283.	2.7	32
62	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. American Journal of Psychiatry, 2016, 173, 465-472.	7.2	77
63	Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia. Expert Review of Neurotherapeutics, 2016, 16, 375-387.	2.8	12
64	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
65	Biomarkers of aggression in dementia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 125-130.	4.8	20
66	Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias. Current Neurology and Neuroscience Reports, 2016, 16, 14.	4.2	56
67	Protective effects of quercetin glycosides, rutin, and isoquercitrin against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in rat pheochromocytoma (PC-12) cells. International Journal of Immunopathology and Pharmacology, 2016, 29, 30-39.	2.1	66
68	Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2016, 24, 70-80.	1.2	39
69	Antioxidant modulation in restoring mitochondrial function in neurodegeneration. International Journal of Neuroscience, 2017, 127, 218-235.	1.6	3
70	Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimer's and Dementia, 2017, 13, 84-100.	0.8	167
71	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. Journal of Alzheimer's Disease, 2017, 56, 929-938.	2.6	306
72	Inappropriate Sexual Behaviors in Dementia. American Journal of Geriatric Psychiatry, 2017, 25, 372-373.	1.2	6
73	Language background in early life may be related to neuropsychiatry symptoms in patients with Alzheimer disease. BMC Geriatrics, 2017, 17, 50.	2.7	2

#	ARTICLE	IF	CITATIONS
74	The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 449-462.	2.6	18
75	Abnormal baseline brain activity in Alzheimer's disease patients with depression: a resting-state functional magnetic resonance imaging study. <i>Neuroradiology</i> , 2017, 59, 709-714.	2.2	5
76	Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation. <i>American Journal of Psychiatry</i> , 2017, 174, 307-308.	7.2	1
77	An update on the advancements in the treatment of agitation in Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 611-620.	1.8	58
78	Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. <i>BMJ Open</i> , 2017, 7, e012759.	1.9	356
79	Non human primate models for Alzheimer's disease-related research and drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 187-200.	5.0	50
80	Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1373-1385.	2.4	8
81	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 440-449.	3.7	240
82	A light therapy for treating Alzheimer's disease. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0
83	Major Neurocognitive Disorders. , 0, , 43-101.		0
84	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 17.	6.2	30
85	Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 259-277.	3.3	13
86	Development of a home-based training program for post-ward geriatric rehabilitation patients with cognitive impairment: study protocol of a randomized-controlled trial. <i>BMC Geriatrics</i> , 2017, 17, 214.	2.7	14
87	The Impact of Respite Programming on Caregiver Resilience in Dementia Care: A Qualitative Examination of Family Caregiver Perspectives. <i>Inquiry (United States)</i> , 2018, 55, 004695801775150.	0.9	26
89	The Progression of Neuropsychiatric Symptoms in Alzheimer's Disease During a Five-Year Follow-Up: Kuopio ALSOVA Study. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1367-1376.	2.6	24
90	Managing Behavioral and Psychological Symptoms of Dementia. <i>Psychiatric Clinics of North America</i> , 2018, 41, 127-139.	1.3	58
91	Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 823-842.	1.8	43
92	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S313-S327.	2.6	31

#	ARTICLE	IF	CITATIONS
93	The stability of neuropsychiatric subsyndromes in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 880-888.	0.8	24
94	Genetic risk for schizophrenia and psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2018, 23, 963-972.	7.9	55
95	Case series of mild behavioral impairment: toward an understanding of the early stages of neurodegenerative diseases affecting behavior and cognition. <i>International Psychogeriatrics</i> , 2018, 30, 273-280.	1.0	29
96	Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study. <i>Alzheimer's and Dementia</i> , 2018, 14, 271-279.	0.8	35
97	Learning Metabolic Brain Networks in MCI and AD by Robustness and Leave-One-Out Analysis: An FDG-PET Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 42-54.	1.9	13
98	Self-reported personality traits are prospectively associated with proxy-reported behavioral and psychological symptoms of dementia at the end of life. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 489-494.	2.7	21
99	Treatment effects of <i>Ginkgo biloba</i> extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. <i>International Psychogeriatrics</i> , 2018, 30, 285-293.	1.0	72
100	Anxiety-like behavior as an early endophenotype in the TgF344-AD rat model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 169-176.	3.1	61
101	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer's Disease: A Case Report. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1363-1369.	2.6	5
102	Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 139-148.	2.6	13
103	Association of Alzheimer's genetic loci with mild behavioral impairment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 727-735.	1.7	49
104	Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders. , 2018, , 467-494.		0
105	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1146-1152.	2.7	11
106	The influence of the individual neuropsychiatric symptoms of people with Alzheimer disease on family caregiver distress—A longitudinal ALSOVA study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1207-1212.	2.7	17
107	Neuropsychiatric Symptoms and Caregiver Burden in Individuals With Alzheimer's Disease: The TEAM-AD VA Cooperative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2018, 31, 177-185.	2.3	39
108	Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1361-1369.	2.7	65
109	The Effects of Music Therapy on Cognition, Psychiatric Symptoms, and Activities of Daily Living in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1347-1358.	2.6	76
110	Lanthanide Functionalized Metal-Organic Coordination Polymer: Toward Novel Turn-On Fluorescent Sensing of Amyloid β -Peptide. <i>Analytical Chemistry</i> , 2018, 90, 12449-12455.	6.5	62

#	ARTICLE	IF	CITATIONS
111	Cognitive Therapy for Dementia Patients: A Systematic Review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 1-26.	1.5	48
112	Italian revised memory and behavior problems checklist (It-RMBPC): validation and psychometric properties in Alzheimer's disease caregivers. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 527-537.	2.9	3
113	“Ours is the Strangest Situation, Ours is Different from Most Peoples”: Spousal Caregiver Perspectives on the Complex Challenges of Dementia Caregiving in Late-Life Marriage. <i>Marriage and Family Review</i> , 2019, 55, 584-600.	1.2	2
114	Depression, subjective cognitive decline, and the risk of neurocognitive disorders. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 70.	6.2	61
115	Contributions of adult neurogenesis to dentate gyrus network activity and computations. <i>Behavioural Brain Research</i> , 2019, 374, 112112.	2.2	61
116	Persons with Dementia Living at Home or in Nursing Homes in Nine Swedish Urban or Rural Municipalities. <i>Healthcare (Switzerland)</i> , 2019, 7, 80.	2.0	5
117	Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 443-454.	2.6	25
118	Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 165, 5-32.	1.8	70
119	The Hyperactivity/Impulsivity/Irritability/Disinhibition/Aggression/Agitation Domain in Alzheimer's Disease: Current Management and Future Directions. <i>Frontiers in Pharmacology</i> , 2019, 10, 1109.	3.5	45
120	Escitalopram for agitation in Alzheimer's disease (SADAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. <i>Alzheimer's and Dementia</i> , 2019, 15, 1427-1436.	0.8	28
121	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 757-768.	2.6	32
122	Differential associations between depression and cognitive function in MCI and AD: a cross-sectional study. <i>International Psychogeriatrics</i> , 2019, 31, 1151-1158.	1.0	16
123	Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease: protocol of the BEAT-IT study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 48.	6.2	14
124	Neurochemical Aspects of Frontotemporal Dementia. , 2019, , 183-214.		0
125	Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 164-169.	2.3	11
126	Protein Chimera-based Ca ²⁺ Rewiring as a Treatment Modality for Neurodegeneration. <i>Current Psychopharmacology</i> , 2019, 8, 27-40.	0.3	0
127	Cortical β -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. <i>Translational Psychiatry</i> , 2019, 9, 123.	4.8	54
128	Delusions in Alzheimer Disease: What Researchers Should Not Forget. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 499-501.	1.2	0

#	ARTICLE	IF	CITATIONS
129	Pharmacokinetics, bioavailability and tissue distribution study of JCC-02, a novel N-methyl-d-aspartate (NMDA) receptor inhibitor, in rats by LC-MS/MS. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 131, 146-152.	4.0	4
130	Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study. <i>BMJ Open</i> , 2019, 9, e031947.	1.9	35
131	High prevalence of sleep disorders and behavioral and psychological symptoms of dementia in late-onset Alzheimer disease. <i>Medicine (United States)</i> , 2019, 98, e18405.	1.0	29
132	Role of Adenosine A _{2A} Receptors in the Central Fatigue of Neurodegenerative Diseases. <i>Journal of Caffeine and Adenosine Research</i> , 2019, 9, 145-156.	0.6	9
133	Bazhu Decoction, a Traditional Chinese Medical Formula, Ameliorates Cognitive Deficits in the 5xFAD Mouse Model of Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1391.	3.5	9
134	Development of bioanalytical HPLC method for simultaneous determination of the antialzheimer, donepezil hydrochloride and the antidepressant, citalopram hydrobromide in raw materials, spiked human plasma and tablets dosage form. <i>Annales Pharmaceutiques Francaises</i> , 2019, 77, 112-120.	1.0	3
135	Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 383-400.	1.2	57
136	The impact of vascular burden on behavioural and psychological symptoms in older adults with dementia: the BEVASDE study. <i>Neurological Sciences</i> , 2020, 41, 165-174.	1.9	16
137	Aromatase (CYP19A1) gene variants, sex steroid levels, and late-life depression. <i>Depression and Anxiety</i> , 2020, 37, 146-155.	4.1	10
138	The duality of human cognition: operations and intentionality in mental life and illness. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 108, 139-148.	6.1	1
139	Individual therapeutic-cognitive intervention of the psychological and behavioural symptoms of patients with dementia (PRESTA study). <i>Revista Científica De La Sociedad De Enfermería Neurológica (English Ed)</i> , 2020, 52, 7-18.	0.1	1
140	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	2.6	39
141	Neuropsychiatric Symptoms in Elderly With Dementia During COVID-19 Pandemic: Definition, Treatment, and Future Directions. <i>Frontiers in Psychiatry</i> , 2020, 11, 579842.	2.6	87
142	Affective Neuropsychiatric Symptoms as Early Signs of Dementia Risk in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1195-1207.	2.6	16
143	Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2020, 45, e463-e468.	1.3	9
144	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by Aβ ₂ -ImmunoTherapy and Cognitive Stimulation. <i>Pharmaceutics</i> , 2020, 12, 944.	4.5	17
145	Apathy and risk of probable incident dementia among community-dwelling older adults. <i>Neurology</i> , 2020, 95, e3280-e3287.	1.1	28
146	The Effectiveness of Non-Pharmacological Interventions on Apathy in Patients With Dementia: A Systematic Review of Systematic Reviews. <i>Worldviews on Evidence-Based Nursing</i> , 2020, 17, 311-318.	2.9	12

#	ARTICLE	IF	CITATIONS
147	Detection and Prediction of Mild Cognitive Impairment in Alzheimer's Disease Mice. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1209-1221.	2.6	4
148	Psychometric Properties of the Neuropsychiatric Inventory: A Review. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1485-1499.	2.6	15
149	Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia. <i>Seminars in Neurology</i> , 2020, 40, 394-410.	1.4	7
150	Interaction of neuropsychiatric symptoms with APOE ϵ 4 and conversion to dementia in MCI patients in a Memory Clinic. <i>Scientific Reports</i> , 2020, 10, 20058.	3.3	13
152	Neuropsychiatric Inventory-Assessed Nighttime Behavior Accompanies, but Does Not Precede, Progressive Cognitive Decline Independent of Alzheimer's Disease Histopathology. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 839-850.	2.6	2
153	Neuropsychiatric Aspects of Alzheimer Dementia. <i>Psychiatric Clinics of North America</i> , 2020, 43, 383-397.	1.3	3
154	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1045-1055.	2.6	52
155	Alpha-terpinyl acetate: A natural monoterpenoid from <i>Elettaria cardamomum</i> as multi-target directed ligand in Alzheimer's disease. <i>Journal of Functional Foods</i> , 2020, 68, 103892.	3.4	39
156	A machine learning-based linguistic battery for diagnosing mild cognitive impairment due to Alzheimer's disease. <i>PLoS ONE</i> , 2020, 15, e0229460.	2.5	5
157	Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer's Disease: Insights From Preclinical Models, Clinical Data, and Future Directions. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 56.	3.4	11
158	May neuropsychiatric symptoms be a potential intervention target to delay functional impairment in Alzheimer's disease?. <i>International Psychogeriatrics</i> , 2020, 32, 689-691.	1.0	5
159	Conceptualizing caregiving activities for persons with dementia (PwD) through a patient work lens. <i>Applied Ergonomics</i> , 2020, 85, 103070.	3.1	22
160	Protein-protein interactions underlying the behavioral and psychological symptoms of dementia (BPSD) and Alzheimer's disease. <i>PLoS ONE</i> , 2020, 15, e0226021.	2.5	13
161	Effects of neuropsychiatric symptoms of dementia on reductions in activities of daily living in patients with Alzheimer's disease. <i>Geriatrics and Gerontology International</i> , 2020, 20, 584-588.	1.5	8
162	The multi-faceted impact of methamphetamine on Alzheimer's disease: From a triggering role to a possible therapeutic use. <i>Ageing Research Reviews</i> , 2020, 60, 101062.	10.9	26
163	Like a bridge over troubled water – a qualitative study of professional caregiver singing and music as a way to enable person-centred care for persons with dementia. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2020, 15, 1735092.	1.6	17
164	Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 35.	6.2	43
165	Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 598-605.	2.7	9

#	ARTICLE	IF	CITATIONS
166	Cerebral amyloid accumulation is associated with distinct structural and functional alterations in the brain of depressed elders with mild cognitive impairment. <i>Journal of Affective Disorders</i> , 2021, 281, 459-466.	4.1	14
167	Association of Cortical and Subcortical β -Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 64-71.	1.8	9
168	Remodeling of projections from ventral hippocampus to prefrontal cortex in Alzheimer's mice. <i>Journal of Comparative Neurology</i> , 2021, 529, 1486-1498.	1.6	5
169	Leaving Life Too Early or Leaving the Decision Too Late in Alzheimer-Type Dementias: Choices and Preferences for Medical Assistance in Dying (MAID). , 2021, , 365-379.		0
170	Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12164.	2.4	32
171	The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-6.	2.7	4
172	Neurological diseases: Sex and gender evidence in stroke, migraine, and Alzheimer's dementia. , 2021, , 229-258.		0
173	Cannabinoids for Agitation in Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 1253-1263.	1.2	12
174	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	8.0	17
175	Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1362-1369.	2.7	16
176	Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer's disease: a systematic review. <i>International Clinical Psychopharmacology</i> , 2021, 36, 169-180.	1.7	8
177	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4440.	4.1	17
178	Behavioural disorders in Alzheimer's disease: the descriptive and predictive role of brain ^{18}F -fluorodesoxyglucose-positron emission tomography. <i>Psychogeriatrics</i> , 2021, 21, 514-520.	1.2	1
179	Physical exercise is effective for neuropsychiatric symptoms in Alzheimer's disease: a systematic review. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 447-456.	0.8	5
180	Neuropsychiatric Symptoms of Alzheimer's Disease in Down Syndrome and Its Impact on Caregiver Distress. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 137-154.	2.6	7
181	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.8	5
182	Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and β -specific lesion patterns. <i>Molecular Neurodegeneration</i> , 2021, 16, 38.	10.8	80
183	Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals. <i>German Journal of Exercise and Sport Research</i> , 2021, 51, 487-494.	1.2	5

#	ARTICLE	IF	CITATIONS
184	Quantitative Assessment of Cortical Excitability in Alzheimer's Dementia and Its Association with Clinical Symptoms: A Systematic Review and Meta-Analyses. Journal of Alzheimer's Disease, 2022, 88, 867-891.	2.6	7
185	Emergent and Non-Emergent Agitation in the Older Adult: Evaluation and Management. Current Geriatrics Reports, 0, , 1.	1.1	0
186	Adjunctive Therapy to Manage Neuropsychiatric Symptoms in Moderate and Severe Dementia: Randomized Clinical Trial Using an Outpatient Version of Tailored Activity Program. Journal of Alzheimer's Disease, 2021, 83, 475-486.	2.6	5
187	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. Neurology, 2021, 97, e1276-e1287.	1.1	44
188	Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia. International Psychogeriatrics, 2021, 33, 1217-1228.	1.0	20
189	Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. Neuroscience and Biobehavioral Reviews, 2021, 127, 647-658.	6.1	31
190	Is bigger better? Towards a mechanistic understanding of neuropsychiatric symptoms in Alzheimer's disease. International Psychogeriatrics, 2021, 33, 1129-1133.	1.0	2
191	Neuropsychiatric Manifestations Across Neurological Conditions. , 2022, , 167-175.		0
192	Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12152.	2.4	3
193	Distinct Patterns of Brain Atrophy associated with Mild Behavioral Impairment in Cognitively Normal Elderly Adults. International Journal of Medical Sciences, 2021, 18, 2950-2956.	2.5	14
194	Depression and Anxiety in Dementia Subjects. Neuropsychiatric Symptoms of Neurological Disease, 2017, , 181-198.	0.3	2
195	Voices from Down Home: Family Caregiver Perspectives on Navigating Care Transitions with Individuals with Dementia in Nova Scotia, Canada. Emerging Issues in Family and Individual Resilience, 2018, , 99-119.	0.2	3
196	Managing Behavioral and Psychological Symptoms of Dementia. Clinics in Geriatric Medicine, 2020, 36, 315-327.	2.6	27
199	Assessment of Medical Decision-making Capacity in Patients With Dementia. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 920-925.	0.8	4
200	Late-onset Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 14-33.	0.8	70
201	Strategic Lesions in the Anterior Thalamic Radiation and Apathy in Early Alzheimer's Disease. PLoS ONE, 2015, 10, e0124998.	2.5	47
202	Cortical brain volume abnormalities associated with few or multiple neuropsychiatric symptoms in Alzheimer's disease. PLoS ONE, 2017, 12, e0177169.	2.5	16
203	NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-2.	2.7	18

#	ARTICLE	IF	CITATIONS
204	PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2015, 2, 1-6.	2.7	12
205	Neuropsychiatric symptoms and executive function impairments in Alzheimer's disease and vascular dementia: The role of subcortical circuits. <i>Dementia E Neuropsychologia</i> , 2019, 13, 293-298.	0.8	17
206	Association between polymorphisms in the promoter region of the apolipoprotein E (APOE) gene and Alzheimer's disease: A meta-analysis. <i>EXCLI Journal</i> , 2017, 16, 921-938.	0.7	12
207	Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review. <i>Current Alzheimer Research</i> , 2016, 14, 61-75.	1.4	35
208	Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1564-e1569.	2.2	24
209	Elevated Cerebrospinal Fluid Norepinephrine in the Elderly can Link Depression and A Reduced Glymphatic System as Risk Factors for Alzheimer's Disease. <i>Journal of Aging Science</i> , 2016, 4, .	0.5	5
210	The doll therapy as a first line treatment for behavioral and psychologic symptoms of dementia in nursing homes residents: a randomized, controlled study. <i>BMC Geriatrics</i> , 2021, 21, 545.	2.7	7
213	<i>Psychogeriatrics</i> . , 2019, , 1-6.		0
214	Study of the Effects of L-tryptophane Nanoparticles on Motor Behavior in Alzheimer's Experimental Models. <i>CNS and Neurological Disorders - Drug Targets</i> , 2019, 18, 44-51.	1.4	6
215	Near infra-red light treatment of Alzheimer's disease. , 2019, , .		0
216	El papel de las especies reactivas de oxígeno y nitrógeno en algunas enfermedades neurodegenerativas. <i>Revista De La Facultad De Medicina, Universidad Nacional Autonoma De Mexico</i> , 2019, 62, 6-19.	0.1	1
217	Reduced Thickness of the Anterior Cingulate Cortex as a Predictor of Amnesic-Mild Cognitive Impairment Conversion to Alzheimer's Disease with Psychosis. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1709-1717.	2.6	5
218	The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1260, 267-281.	1.6	4
219	<i>Psychiatric Disorders in Dementia</i> . , 2021, , 317-385.		0
220	Sex-specificities in anxiety and depressive symptoms across the lifespan and their links with multimodal neuroimaging. <i>Journal of Affective Disorders</i> , 2022, 296, 593-602.	4.1	5
221	The Sleep-Wake System and Alzheimer's Disease. <i>Advances in Psychology, Mental Health, and Behavioral Studies</i> , 0, , 339-365.	0.1	0
222	<i>Psychogeriatrics</i> . , 2021, , 1-7.		0
223	Clinical features and brain structural changes in magnetic resonance imaging in Alzheimer's disease patients with apathy. <i>Aging</i> , 2020, 12, 19083-19094.	3.1	1

#	ARTICLE	IF	CITATIONS
224	Differential effects of chronic stress on anxiety-like behavior and contextual fear conditioning in the TgF344-AD rat model of Alzheimer's disease. Behavioural Brain Research, 2022, 418, 113661.	2.2	4
225	A Comparison of Behavioral and Psychological Symptoms of Dementia (BPSD) and BPSD Sub-Syndromes in Early-Onset and Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 691-699.	2.6	30
226	Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: mediation by amyloid pathology. Translational Psychiatry, 2021, 11, 577.	4.8	11
227	Psychogeriatrics. , 2021, , 4017-4023.		0
228	Clinical features and brain structural changes in magnetic resonance imaging in Alzheimer's disease patients with apathy. Aging, 2020, 12, 19083-19094.	3.1	4
229	Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?. Frontiers in Psychiatry, 2021, 12, 808724.	2.6	4
230	Psychosis in Alzheimer disease – mechanisms, genetics and therapeutic opportunities. Nature Reviews Neurology, 2022, 18, 131-144.	10.1	62
231	Exploring how caregivers for people living with dementia use strategies to overcome work system constraints. Applied Ergonomics, 2022, 101, 103689.	3.1	0
232	Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2023, 19, 4498-4506.	0.8	17
233	Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 718949.	3.4	9
235	Quantifying the qualitative: exploring epistemic network analysis as a method to study work system interactions. Ergonomics, 2022, 65, 1434-1449.	2.1	5
236	Visit-To-Visit Blood Pressure Variability and Subthreshold Depressive Symptoms in Older Adults. American Journal of Geriatric Psychiatry, 2022, 30, 1110-1119.	1.2	11
237	Neuropsychiatric Inventory – Questionnaire Assessed Nighttime Behaviors in Cognitively Asymptomatic Patients with Pathologically Confirmed Alzheimer's Disease Predict More Rapid Cognitive Deterioration. Journal of Alzheimer's Disease, 2022, 86, 1137-1147.	2.6	3
238	A longitudinal investigation of A β , anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831.	0.8	14
241	Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems. Frontiers in Aging Neuroscience, 2022, 14, .	3.4	6
242	The Brilliance of the Zebrafish Model: Perception on Behavior and Alzheimer's Disease. Frontiers in Behavioral Neuroscience, 0, 16, .	2.0	8
243	Alzheimer diseases. , 2023, , 313-336.		3
244	Relations of neuropsychiatric symptoms with disease stage, sex, and daily function in mild cognitive impairment and dementia due to Alzheimer's disease: A cross-sectional study. Journal of Psychosomatic Research, 2022, 161, 110994.	2.6	6

#	ARTICLE	IF	CITATIONS
245	Empirical and Authoritative Classification of Neuropsychiatric Syndromes in Neurocognitive Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 2023, 35, 39-47.	1.8	1
246	Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta-analysis. Brain and Behavior, 2022, 12, .	2.2	4
247	Characterization of Apathy-Like Behaviors in the 5xFAD Mouse Model of Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0
249	Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases. Ageing Research Reviews, 2023, 84, 101819.	10.9	9
250	Disrupted topological organization of functional brain networks in Alzheimer's disease patients with depressive symptoms. BMC Psychiatry, 2022, 22, .	2.6	5
251	Effect of online tDCS to left somatomotor cortex on neuropsychiatric symptoms among older adults at risk for dementia. Cortex, 2023, 159, 131-141.	2.4	4
252	Dementia and Mild Neurocognitive Disorders. , 2022, , .		0
253	A "Prosthetic Environment" for Individuals with Dementia. SpringerBriefs in Applied Sciences and Technology, 2023, , 69-80.	0.4	0
254	Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline. Psychiatric Research and Clinical Practice, 2023, 5, 4-15.	2.4	2
255	Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective. Journal of Alzheimer's Disease, 2023, 92, 1131-1146.	2.6	3
256	Sex Differences in Alzheimer's Disease. Neurologic Clinics, 2023, 41, 343-358.	1.8	9
257	Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimer's disease. Neurobiology of Aging, 2023, 126, 113-122.	3.1	4
258	Evaluation and Management of Dementia. , 2022, , 112-128.		0
259	Lower cognitive function attenuates the convergence between self-ratings and observer ratings of depressive symptoms in late-life cognitive impairment. Brain and Behavior, 2023, 13, .	2.2	1
260	Effects of Sideritis scardica Extract on Scopolamine-Induced Learning and Memory Impairment in Mice. Journal of Alzheimer's Disease, 2023, 92, 1289-1302.	2.6	5
261	A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2023, 24, 691-703.	1.8	1
262	The effect of music therapy on cognitive functions in patients with Alzheimer's disease: a systematic review of randomized controlled trials. Alzheimer's Research and Therapy, 2023, 15, .	6.2	8
263	Aberrant Dopamine System Function in the Ferrous Amyloid Buthionine (FAB) Rat Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 7196.	4.1	4

#	ARTICLE	IF	CITATIONS
264	The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer's disease: a natural language processing study. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	6.2	2
265	Association Between False Memories and Delusions in Alzheimer Disease. <i>JAMA Psychiatry</i> , 2023, 80, 700.	11.0	0
266	Association of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort. <i>JAMA Neurology</i> , 2023, 80, 949.	9.0	7
267	Neuropsychiatric Symptoms of Alzheimer's Disease: An Anatomic-Genetic Framework for Treatment Development. <i>Journal of Alzheimer's Disease</i> , 2023, 95, 53-68.	2.6	1
268	Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2023, 15, .	2.4	0
269	Uric acid index is a risk for mild cognitive impairment in type 2 diabetes. <i>Hormones</i> , 2023, 22, 425-439.	1.9	1
270	Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2023, 9, .	3.7	0
271	Apathy-like behaviour in tau mouse models of Alzheimer's disease and frontotemporal dementia. <i>Behavioural Brain Research</i> , 2024, 456, 114707.	2.2	0
272	Oligonol ameliorates liver function and brain function in the 5 Å— FAD mouse model: transcriptional and cellular analysis. <i>Food and Function</i> , 0, , .	4.6	0
273	Psychiatric Disorders Before and After Dementia Diagnosis. <i>JAMA Network Open</i> , 2023, 6, e2338080.	5.9	0
274	Common Neuropsychiatric Symptoms in Alzheimer's Disease, Mild Cognitive Impairment, and Subjective Memory Complaints: A Unified Framework. <i>Current Alzheimer Research</i> , 2023, 20, .	1.4	0
275	Nourishing the Cognition with Millets: A Comprehensive Review of Their Nutritional Impact and Potential as Cognitive Enhancers. <i>Molecular Nutrition and Food Research</i> , 2023, 67, .	3.3	1
276	Association of Cerebrovascular Imaging Biomarkers, Depression, and Anxiety, with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease Reports</i> , 2023, 7, 1237-1246.	2.2	0
277	Neuropsychiatric Symptoms and In Vivo Alzheimer's Biomarkers in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2023, 96, 1827-1836.	2.6	0
278	Context is not key: Detecting Alzheimer's disease with both classical and transformer-based neural language models. , 2023, , 100046.		0
279	Generation and Characterization of a Human-Derived and Induced Pluripotent Stem Cell (iPSC) Line from an Alzheimer's Disease Patient with Neuropsychiatric Symptoms. <i>Biomedicines</i> , 2023, 11, 3313.	3.2	0
280	Alleviation of behavioral deficits, amyloid- β deposition, and mitochondrial structure damage associated with mitophagy upregulation in AD animal models via AAV9-IGF-1 treatment. <i>Brain Research</i> , 2024, 1827, 148743.	2.2	0
281	Distinguishing features of depression in dementia from primary psychiatric disease. <i>Discover Mental Health</i> , 2024, 4, .	2.0	1

#	ARTICLE	IF	CITATIONS
282	Depression and Agitation Factors Are Related to Regional Brain Atrophy and Faster Longitudinal Cognitive Decline in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2024, 97, 1341-1351.	2.6	1
283	Knowledge Structure and Emerging Trends of Mild Cognitive Impairment with Dyssomnias in Recent 20 Years: A Bibliometric Analysis via CiteSpace and VOSviewer. <i>Behavioural Neurology</i> , 2024, 2024, 1-18.	2.1	0
284	Mild behavioral impairment in early Alzheimer's disease and its association with APOE and BDNF risk genetic polymorphisms. <i>Alzheimer's Research and Therapy</i> , 2024, 16, .	6.2	0
285	Extracts of <i>Sideritis scardica</i> and <i>Clinopodium vulgare</i> Alleviate Cognitive Impairments in Scopolamine-Induced Rat Dementia. <i>International Journal of Molecular Sciences</i> , 2024, 25, 1840.	4.1	0
286	Discourse and Conversation Impairments in Patients with Dementia. , 2023, , 37-51.		0
287	Neuropsychiatric and Cognitive Symptoms: Two Sides of the Same Coin?. <i>Journal of Alzheimer's Disease</i> , 2024, 98, 75-78.	2.6	0
288	Exploring the Genetic Landscape of Mild Behavioral Impairment as an Early Marker of Cognitive Decline: An Updated Review Focusing on Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2645.	4.1	0
289	Therapeutic potential of clinically proven natural products in the management of dementia. <i>Heliyon</i> , 2024, 10, e27233.	3.2	0
290	Preliminary evidence for preserved synaptic density in late-life depression. <i>Translational Psychiatry</i> , 2024, 14, .	4.8	0
291	Prevalence of mild behavioural impairment and its association with cognitive and functional impairment in normal cognition, mild cognitive impairment, and mild <scp>Alzheimer's</scp> dementia. <i>Psychogeriatrics</i> , 2024, 24, 555-564.	1.2	0
292	Neuropsychiatric symptoms profile and markers of Alzheimer disease's type pathology in patients with Lewy body dementias. <i>Brain Research</i> , 2024, 1833, 148881.	2.2	0